The recent developments of the vaccine reveal peak efficiency for high-risk people i.e. people over 65 with some underlying health issues.
With no major safety concerns, the virus is all set to be sent for authorization and put under scrutiny by the FDA. The vaccine will also be up for peer reviews and an independent advisory committee will give recommendations to the agency.
— Pfizer Inc. (@pfizer) November 18, 2020
Produced with the German biotechnology firm BioNTech, the good news of the vaccine comes at a time when countries all across have been succumbing to the deadly coronavirus.
It is estimated that the second week of December will hold an influential panel of outside experts publicly to scrutinize the vaccine. The committee will also scrutinize data from biotechnology company Moderna in the week to come. Moderna is another company that has claimed that early analysis of their vaccine has shown nearly 95% efficiency.
By the end of 2020, the US officials anticipate having 40 million doses of both the Moderna and Pfizer vaccine both of which require two doses for a person. Which will vaccinate 20 million people across the USA by the end of the year.
Pfizer will produce 50 million vaccines by the end of 2020 and half of the vaccines will be distributed globally while half is anticipated to be distributed across the USA.
The FDA staff examine the vaccine data at least for a year before they take it to their advisory committee. However, since February 2020, the FDA has used its power to authorize emergency use for various coronavirus tests and treatments.
The Pfizer vaccine also comes under the same category of emergency use authorization during a health emergency. Previously the FDA authorized a vaccine under emergency use authorization once in 2005 for anthrax.
Source: Washington Post, NDTV News
By: Ayusha Chalise